MX362001B - Composición farmacéutica que comprende un agente terapéutico a base de hemoglobina modificada para tratamiento dirigido al cáncer e imagenología diagnóstica. - Google Patents
Composición farmacéutica que comprende un agente terapéutico a base de hemoglobina modificada para tratamiento dirigido al cáncer e imagenología diagnóstica.Info
- Publication number
- MX362001B MX362001B MX2015015555A MX2015015555A MX362001B MX 362001 B MX362001 B MX 362001B MX 2015015555 A MX2015015555 A MX 2015015555A MX 2015015555 A MX2015015555 A MX 2015015555A MX 362001 B MX362001 B MX 362001B
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- hemoglobin
- therapeutic agent
- pharmaceutical composition
- diagnostic imaging
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 6
- 201000011510 cancer Diseases 0.000 title abstract 5
- 239000003814 drug Substances 0.000 title abstract 4
- 229940124597 therapeutic agent Drugs 0.000 title abstract 3
- 238000002059 diagnostic imaging Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000008685 targeting Effects 0.000 title 1
- 102000001554 Hemoglobins Human genes 0.000 abstract 5
- 108010054147 Hemoglobins Proteins 0.000 abstract 5
- 208000003174 Brain Neoplasms Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 abstract 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 abstract 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 201000004101 esophageal cancer Diseases 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 201000010536 head and neck cancer Diseases 0.000 abstract 1
- 208000014829 head and neck neoplasm Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 238000010859 live-cell imaging Methods 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 229940126585 therapeutic drug Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6445—Haemoglobin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
Abstract
La presente invención se refiere una composición farmacéutica que contiene un agente terapéutico a base de hemoglobina para tratar el cáncer. La fracción de hemoglobina puede dirigirse a las células cancerígenas y la fracción terapéutica (es decir, el agente activo/fármaco terapéutico) puede eliminar las células cancerígenas en forma eficiente. El agente terapéutico a base de hemoglobina usado en la presente invención, se puede usar en el tratamiento de varios cánceres tales como: el cáncer pancreático, la leucemia, el cáncer de cabeza y cuello, el cáncer colorectal, el cáncer pulmonar, el cáncer de mama, el cáncer hepático, el cáncer nasofaríngeo, el cáncer esofágico, el cáncer de próstata, el cáncer estomacal y el cáncer cerebral. La composición se puede usar sola o en combinación con otro(s) agente(s) terapéutico(s) tal(es) como un agente quimioterapéutico, para proporcionar un efecto sinergístico en el tratamiento del cáncer, inhibiendo la metástasis y/o reduciendo la recurrencia. El conjugado 5FU de dos tintes a base de hemoglobina y/o el conjugado 5FU de un tinte a base de hemoglobina que está siendo reivindicado, también se pueden usar en la imagenología de célula viva y en la imágenología diagnóstica.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361822463P | 2013-05-13 | 2013-05-13 | |
| PCT/US2014/037749 WO2014186301A1 (en) | 2013-05-13 | 2014-05-13 | Pharmaceutical composition comprising modified hemoglobin- based therapeutic agent for cancer targeting treatment and diagnostic imaging |
| US14/275,885 US9636404B2 (en) | 2013-05-13 | 2014-05-13 | Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015015555A MX2015015555A (es) | 2016-05-09 |
| MX362001B true MX362001B (es) | 2019-01-03 |
Family
ID=51864923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015015555A MX362001B (es) | 2013-05-13 | 2014-05-13 | Composición farmacéutica que comprende un agente terapéutico a base de hemoglobina modificada para tratamiento dirigido al cáncer e imagenología diagnóstica. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9636404B2 (es) |
| EP (1) | EP3001813B1 (es) |
| JP (1) | JP6392855B2 (es) |
| KR (1) | KR102013015B1 (es) |
| CN (1) | CN105407911B (es) |
| AU (1) | AU2014265659B2 (es) |
| BR (1) | BR112015028340A2 (es) |
| CA (1) | CA2911414C (es) |
| CL (1) | CL2015003343A1 (es) |
| EA (1) | EA032164B1 (es) |
| HK (2) | HK1222574A1 (es) |
| IL (1) | IL242422B (es) |
| MA (1) | MA38571B1 (es) |
| MX (1) | MX362001B (es) |
| MY (1) | MY176175A (es) |
| PH (1) | PH12015502536A1 (es) |
| SA (1) | SA515370134B1 (es) |
| SG (1) | SG11201509042YA (es) |
| TW (1) | TWI610685B (es) |
| WO (1) | WO2014186301A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9636404B2 (en) * | 2013-05-13 | 2017-05-02 | Vision Global Holdings Ltd. | Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging |
| JP6564369B2 (ja) | 2013-12-09 | 2019-08-21 | デュレクト コーポレイション | 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法 |
| US9814759B2 (en) * | 2014-07-02 | 2017-11-14 | Cheer Global Ltd. | Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment |
| JP2017529837A (ja) | 2014-09-03 | 2017-10-12 | イミュノジェン・インコーポレーテッド | 細胞結合剤及び細胞毒性剤を含む複合体 |
| TR201606102A2 (tr) * | 2016-05-10 | 2016-10-21 | Tolgay Tuyan Ilhan | Karin i̇çi̇ uygulanan kanser tedavi̇leri̇nde oksi̇jen konsantrasyonu ölçümü yapabi̇len ve veri̇len oksi̇jen dozaji üzeri̇nde deği̇şi̇kli̇k yapmayi sağlayan ci̇haz |
| EP3471775A4 (en) * | 2016-06-21 | 2020-02-19 | Therapure Biopharma Inc. | HEMOGLOBIN-TARGETED DRUG ADMINISTRATION FOR CANCER TREATMENT |
| EP3555627B1 (en) | 2016-12-14 | 2023-11-22 | Purdue Research Foundation | Fibroblast activation protein (fap)-targeted imaging and therapy |
| US11560384B2 (en) | 2017-05-04 | 2023-01-24 | University Of Utah Research Foundation | Benzonorbornadiene derivatives and reactions thereof |
| CN107153771B (zh) * | 2017-05-17 | 2020-06-30 | 许昌学院 | 一种药物分子的同步控制方法及其应用 |
| WO2019018403A1 (en) | 2017-07-18 | 2019-01-24 | Virtech Bio, Llc | BLOOD SUBSTITUTES COMPRISING HEMOGLOBIN AND METHODS OF MAKING |
| CA3144719A1 (en) * | 2019-07-19 | 2021-01-28 | Cheer Global Limited | Hemoglobin-based therapeutic agents |
| CN114605338B (zh) * | 2022-05-11 | 2022-10-28 | 深圳厚存纳米药业有限公司 | 一种含尿嘧啶衍生物的纳米粒、核酸纳米复合物及其制备方法和用途 |
| CN116068189A (zh) * | 2023-04-07 | 2023-05-05 | 吉林重明生物科技有限公司 | 早期癌检测试剂及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4584130A (en) * | 1985-03-29 | 1986-04-22 | University Of Maryland | Intramolecularly cross-linked hemoglobin and method of preparation |
| DE3675588D1 (de) * | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US5688488A (en) * | 1989-04-03 | 1997-11-18 | Purdue Research Foundation | Composition and method for tumor imaging |
| MC2260A1 (fr) * | 1990-06-18 | 1993-04-26 | Dow Chemical Co | Formulations de produits radiopharmaceutiques,leur methode d'administration et leur procede de preparation |
| EP0611306B1 (en) * | 1991-11-08 | 1998-07-08 | Somatogen, Inc. | Hemoglobins as drug delivery agents |
| WO1995029925A1 (en) * | 1994-04-29 | 1995-11-09 | The Curators Of The University Of Missouri | Thioether compounds for use in preparing bifunctional chelating agents for therapeutic radiopharmaceuticals |
| US5998361A (en) * | 1996-10-18 | 1999-12-07 | University Of Maryland At Baltimore | Polymerized hemoglobin |
| US20050059576A1 (en) * | 1998-04-30 | 2005-03-17 | Adamson J. Gordon | Targeted delivery of antiviral compounds through hemoglobin bioconjugates |
| CA2236344A1 (en) * | 1998-04-30 | 1999-10-30 | Hemosol Inc. | Hemoglobin-haptoglobin complexes |
| ATE377608T1 (de) * | 2003-04-17 | 2007-11-15 | Ezio Panzeri | Hemoglobin konjugate |
| US7235639B2 (en) | 2003-04-23 | 2007-06-26 | Ezio Panzeri | Hemoglobin conjugates |
| BRPI0921586A2 (pt) | 2008-11-18 | 2019-09-24 | Merrimack Pharmaceuticals Inc | articuladores de albumina de soro humana e conjugados destes |
| US7989593B1 (en) * | 2010-05-27 | 2011-08-02 | Bing Lou Wong | Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof |
| US8048856B1 (en) * | 2010-06-23 | 2011-11-01 | Billion King, Ltd. | Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition |
| US8084581B1 (en) * | 2011-04-29 | 2011-12-27 | Bing Lou Wong | Method for removing unmodified hemoglobin from cross-linked hemoglobin solutions including polymeric hemoglobin with a high temperature short time heat treatment apparatus |
| US20130052232A1 (en) * | 2011-08-31 | 2013-02-28 | Bing Lou Wong | Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking |
| US20140106004A1 (en) * | 2012-10-12 | 2014-04-17 | Bing Lou Wong | Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence |
| US9636404B2 (en) * | 2013-05-13 | 2017-05-02 | Vision Global Holdings Ltd. | Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging |
-
2014
- 2014-05-13 US US14/275,885 patent/US9636404B2/en active Active
- 2014-05-13 BR BR112015028340A patent/BR112015028340A2/pt not_active Application Discontinuation
- 2014-05-13 CN CN201480040021.4A patent/CN105407911B/zh active Active
- 2014-05-13 AU AU2014265659A patent/AU2014265659B2/en active Active
- 2014-05-13 MA MA38571A patent/MA38571B1/fr unknown
- 2014-05-13 TW TW103116929A patent/TWI610685B/zh not_active IP Right Cessation
- 2014-05-13 EA EA201501065A patent/EA032164B1/ru not_active IP Right Cessation
- 2014-05-13 MX MX2015015555A patent/MX362001B/es active IP Right Grant
- 2014-05-13 WO PCT/US2014/037749 patent/WO2014186301A1/en active Application Filing
- 2014-05-13 CA CA2911414A patent/CA2911414C/en active Active
- 2014-05-13 EP EP14798660.8A patent/EP3001813B1/en active Active
- 2014-05-13 KR KR1020157032973A patent/KR102013015B1/ko active IP Right Grant
- 2014-05-13 SG SG11201509042YA patent/SG11201509042YA/en unknown
- 2014-05-13 MY MYPI2015703946A patent/MY176175A/en unknown
- 2014-05-13 JP JP2016514013A patent/JP6392855B2/ja active Active
-
2015
- 2015-11-03 IL IL242422A patent/IL242422B/en not_active IP Right Cessation
- 2015-11-05 PH PH12015502536A patent/PH12015502536A1/en unknown
- 2015-11-12 SA SA515370134A patent/SA515370134B1/ar unknown
- 2015-11-13 CL CL2015003343A patent/CL2015003343A1/es unknown
-
2016
- 2016-09-13 HK HK16110826.1A patent/HK1222574A1/zh unknown
- 2016-09-29 HK HK16111399.6A patent/HK1223037A1/zh unknown
-
2017
- 2017-03-27 US US15/469,978 patent/US10322180B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502536A1 (en) | Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging | |
| TW201613960A (en) | Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment | |
| MX2019011494A (es) | Conjugados de anticuerpo-farmaco (adc) de duocarmicina que muestran actividad antitumoral in vivo mejorada. | |
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| MX2017003246A (es) | Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer. | |
| MX2022014277A (es) | Metodos para una mejor administracion de agentes activos a tumores. | |
| TW201613589A (en) | Combination methods for treating cancers | |
| EA201591924A1 (ru) | Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10 | |
| PH12015501995B1 (en) | Pharmaceutical composition comprising albumin-binding arginine deiminase for cancer targeting treatment | |
| EA201101651A1 (ru) | Непрерывное введение интегриновых лигандов для лечения рака | |
| WO2016080810A3 (ko) | 바이구아나이드 화합물 및 이의 용도 | |
| EA201500301A1 (ru) | Содержащая носитель кислорода на основе гемоглобина фармацевтическая композиция для адресного лечения рака и предотвращения рецидивов рака | |
| MX2017014641A (es) | Composiciones y metodos para inhibir la expresion del gen de factor inducible por hipoxia alfa (hif2alfa). | |
| MX2018007823A (es) | Terapia de combinacion de bromodominio e inhibidor de proteina extra terminal. | |
| MX2016009284A (es) | Construcciones dirigidas a receptor y sus usos. | |
| MX2015015434A (es) | Corroles dirigidas para toxicidad tumoral y rm. | |
| BR112015005443A2 (pt) | tratamento combinado com fármaco interferente de netrina-1 e fármaco quimioterápico | |
| BR112014010938A2 (pt) | compostos de 5-(piridin-2-il-amino)-pirazina-2-carbonitrila e seu uso terapêutico | |
| WO2016191703A3 (en) | Tumor deliverable iron and protein synthesis inhibitors as a new class of drugs for the diagnosis and treatment of cancer | |
| EA201500579A1 (ru) | Комбинированная терапия с использованием воласертиба | |
| BR112018011203A2 (pt) | terapia de combinação para câncer | |
| EA201600409A1 (ru) | Красный пигмент группы антрахинонов, способ получения красного пигмента штамма гриба penicillium oxalicum var. armeniaca, продукт способа, его применение, фармацевтическая композиция и способ профилактики и/или лечения онкологических заболеваний | |
| TH156797A (th) | การใช้ของ 3-(r)-[3-(2-เมทอกซีเฟนิลไทโอ)-2-(s)-เมทิล-โพรพิล]แอมิโน-3,4-ไดไฮโดร-2h-1,5-เบนโซซาไทอีพีนสำหรับการบำบัดมะเร็งและโดยเฉพาะอย่างยิ่งสำหรับการป้องกันและ/หรือการบำบัดการแพร่กระจายของมะเร็ง | |
| MX2018003308A (es) | Suministro localizado de agente anti-fuctactico para tratamiento del cancer. | |
| NZ748422A (en) | Heterocyclic glutaminase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |